Belgian Competition Authority Carries Out On Premise Inspections of Pharmaceutical Firms
- 08/10/2019
- Articles
The Belgian Competition Authority (“BCA”) just published a press release indicating that it is currently carrying out inspections at the premises of unspecified pharmaceutical firms which are suspected of hindering the market entry of biosimilar rivals of established medicines (see, attached press release in three language versions).
The BCA will inquire whether any such firm violated applicable competition rules, including Articles 101 and 102, Treaty on the Functioning of the European Union and the equivalent provisions of Belgian law.
